All Pathways
Pulmonary MedicineManagement

ARDS Management (ATS 2024)

ARDS Management (ATS 2024): Suspected ARDS → Berlin Criteria Met? → ARDS Severity (P/F Ratio) → Lung-Protective Ventilation → Adequate Response?.

Interactive Decision Tree

Mini Map

Algorithm Steps

  1. Start

    Suspected ARDS

    Acute hypoxemic respiratory failure with bilateral infiltrates

    1. Decision

      Berlin Criteria Met?

      Confirm ARDS diagnosis

      • Timing: Within 1 week of insult/worsening symptoms
      • Imaging: Bilateral opacities (CXR/CT)
      • Origin: Not fully explained by cardiac failure/fluid overload
      • Oxygenation: P/F ratio ≤300 with PEEP ≥5
      1. Decision

        ARDS Severity (P/F Ratio)

        On PEEP ≥5 cmH2O

        • Mild: P/F 201-300 mmHg
        • Moderate: P/F 101-200 mmHg
        • Severe: P/F ≤100 mmHg
        1. Action

          Lung-Protective Ventilation

          Foundation of ARDS management

          • Low Tidal Volume: 4-6 mL/kg IBW (target 6)
          • Plateau Pressure: ≤30 cmH2O
          • Driving Pressure: <15 cmH2O
          • PEEP: Use higher PEEP/FiO2 table for moderate-severe
          • Target: SpO2 88-95%, pH 7.30-7.45
          1. Decision

            Adequate Response?

            After 12-24h of lung-protective ventilation

            • Improving: P/F ratio increasing, FiO2 weaning
            • Refractory: Persistent severe hypoxemia (P/F <150)
            1. Action

              Continue & Wean

              Gradual liberation from ventilator

              • Continue lung-protective settings
              • Daily SBT when improving
              • Wean FiO2 and PEEP as tolerated
              • Early mobilization when stable
              1. Outcome

                Recovery & Extubation

                Successful liberation from ventilator

                • Daily spontaneous awakening trial
                • Daily spontaneous breathing trial
                • Post-ICU rehabilitation
                • Screen for PICS
            2. Action

              Rescue Therapies

              For moderate-severe ARDS not responding

              • Prone positioning (strong evidence)
              • Neuromuscular blockade (conditional)
              • Corticosteroids (conditional)
              • Higher PEEP strategy
              1. Action

                Prone Positioning

                For P/F <150 within 36h of intubation

                • Duration: ≥16 hours per session
                • Continue until P/F >150 for 4h supine
                • Contraindications: Spine instability, open abdomen, facial trauma
                • Team training essential
                1. Decision

                  Still Refractory?

                  Despite prone + NMB + steroids

                  1. Action

                    Optimized Supportive Care

                    Conservative management

                    • Conservative fluid strategy
                    • Nutrition: Enteral preferred
                    • DVT prophylaxis
                    • Stress ulcer prophylaxis
                    • Minimize sedation
                  2. Decision

                    ECMO Candidate?

                    VV-ECMO for severe refractory ARDS

                    • P/F <80 for >6h OR P/F <50 for >3h
                    • pH <7.25 with PaCO2 >60 for >6h
                    • Age typically <65
                    • Mechanical ventilation <7 days
                    • No contraindications
                    1. Action

                      VV-ECMO

                      Transfer to ECMO center

                      • Venovenous ECMO preferred
                      • Ultra-protective ventilation on ECMO
                      • Specialized center required
                      • ATS 2024: Conditional recommendation
                      1. Outcome

                        Goals of Care Discussion

                        If not improving despite all measures

                        • Family meeting
                        • Palliative care consultation
                        • Discuss prognosis honestly
              2. Action

                Neuromuscular Blockade

                For early severe ARDS

                • Cisatracurium infusion for 48h
                • With deep sedation
                • For P/F <150 in first 48h
                • ATS 2024: Conditional recommendation
              3. Action

                Corticosteroids

                ATS 2024 conditional recommendation

                • Dexamethasone 20mg x 5d then 10mg x 5d
                • Or Methylprednisolone 1-2 mg/kg/day
                • Start within 14 days of ARDS onset
                • Moderate certainty of benefit

Guideline Source

An Update on Management of Adult Patients with ARDS: ATS Clinical Practice Guideline 2024

Clinical Safety Information

Clinical Decision Support — Not a Substitute for Clinical Judgment

Individual patient factors may require deviation from these recommendations.

Known Limitations

  • ECMO availability varies by center
  • Specific ventilator settings require individual titration
  • Does not address pediatric ARDS (PARDS)
  • Neuromuscular blockade duration controversial

Contraindicated Populations

pediatric

Applicable Regions

USGlobal

Global: Berlin criteria and lung-protective ventilation universally applicable

Version 1Next review: 2027-01-01

Frequently Asked Questions

What is the ARDS Management (ATS 2024)?

The ARDS Management (ATS 2024) is a management clinical algorithm for Pulmonary Medicine. It provides a structured decision tree to guide clinical decision-making, based on An Update on Management of Adult Patients with ARDS: ATS Clinical Practice Guideline 2024.

What guideline is the ARDS Management (ATS 2024) based on?

This algorithm is based on An Update on Management of Adult Patients with ARDS: ATS Clinical Practice Guideline 2024 (DOI: 10.1164/rccm.202311-2011ST).

What are the limitations of the ARDS Management (ATS 2024)?

Known limitations include: ECMO availability varies by center; Specific ventilator settings require individual titration; Does not address pediatric ARDS (PARDS); Neuromuscular blockade duration controversial. Individual patient factors may require deviation from these recommendations.

Get AI-Powered Analysis Alongside This Algorithm

In AttendMe.ai, the ARDS Management (ATS 2024) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.

Try AttendMe Free